CStone Pharmaceuticals disclosed in a Next Day Disclosure Return on 17 June 2026 that it repurchased 1.00 million ordinary shares on the Hong Kong Stock Exchange the same day. The shares were bought at prices ranging from HKD 4.53 to HKD 4.83, for a total consideration of HKD 4.62 million.

Including earlier transactions—6,000 shares on 15 June at an average HKD 4.66 and 1.33 million shares on 16 June at an average HKD 4.68—the company has acquired 2.34 million shares since 15 June. These repurchases represent 0.17 % of the 1.60 billion shares outstanding when the current buyback mandate was approved on 25 June 2025.

All 2.34 million repurchased shares are earmarked for cancellation, though the company’s issued share capital remains unchanged at 1.60 billion shares until the cancellations are effected.

Under the 25 June 2025 shareholder mandate, CStone Pharmaceuticals is authorized to repurchase up to 136.45 million shares. After the latest transactions, approximately 134.11 million shares remain available under the mandate. In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of any treasury shares until 17 July 2026.